Fenofibrate add-on therapy improves transplant-free survival in primary biliary cholangitis patients - PubMed
3 hours ago
- #Fenofibrate
- #Primary Biliary Cholangitis
- #Transplant-Free Survival
- Fenofibrate as an add-on therapy improves transplant-free survival in PBC patients who have a suboptimal response to UDCA.
- The study included 160 PBC patients and found significant improvements in ALP and GGT levels after one year of fenofibrate treatment.
- Transplant-free survival rates at 5 and 10 years were significantly higher in the fenofibrate group compared to UDCA monotherapy.
- Adverse events occurred in 25.6% of patients, with liver injury being the most frequent complication.
- The study concludes that fenofibrate not only improves biochemical responses but also enhances long-term transplant-free survival, though monitoring for liver injury is important.